
CLAIMS

1. Use of an anti-seizure effective amount of a compound of Formula (I)

Formula (I)



(4-amino-8-(2-fluoro-6-methoxy-phenyl)-N-propyl-cinnoline-3-carboxamide) or a pharmaceutically acceptable salt thereof, in a pharmaceutically acceptable carrier, in the manufacture of a medicament for providing anti-seizure effects in a subject.

2. The use of claim 1, wherein the subject has epilepsy.

3. The use of claim 2, wherein the epilepsy is idiopathic generalized epilepsy, photosensitive epilepsy, or genetic absence epilepsy.

4. The use of claim 3, wherein the idiopathic generalized epilepsy is childhood absence epilepsy, juvenile absence epilepsy, or Dravet syndrome.

5. The use of claim 1, wherein the seizures are absence seizures, focal seizures, complex partial seizures, tonic-clonic seizures, grand mal seizures, myoclonic seizures, atonic seizures, audiogenic seizures, or clonic seizures.

6. The use of claim 1, wherein the effective amount is from about 0.1 to 100 mg/kg.

7. The use of claim 6, wherein the effective amount is about 0.1 mg/kg, about 0.3 mg/kg, about 1.0 mg/kg, about 3.0 mg/kg, about 10 mg/kg, about 30 mg/kg, or about 100 mg/kg.

8. The use of claim 6 or 7, wherein the compound is to be administered by oral administration.

9. The use of claim 1, wherein the compound is to be administered once, twice, three or four times daily.

10. The use of claim 1, wherein the compound is to be administered at least 10 minutes before onset of a seizure episode.

11. The use of claim 1, wherein the subject is to be administered an additional compound.

12. The use of claim 11, wherein the additional compound is selected from brivaracetam, cannabidiol, carbamazepine, cenobamate, chlordiazepoxide, clobazam, clonazepam, diazepam, eslicarbazepine, ethosuximide, felbamate, fosphenytoin, gabapentin, ganaxolone, lacosamide, lamotrigine, levetiracetam, midazolam, oxcarbazepine, perampanel, phenobarbital, phenytoin, pregabalin, primidone, rufinamide, secobarbital, stiripentol, tiagabine, topiramate, valproate, vigabatrin, or zonisamide.

13. The use of claim 1, wherein the subject is a human or non-human mammal.

14. The use of claim 13, wherein the subject is a canine or feline subject.